SciELO - Scientific Electronic Library Online

 
vol.33Vacunación con SOBERANA®02 y SOBERANA®Plus en trabajadores: éxito en el enfrentamiento a la pandemia de COVID-19Evaluación de una vacuna preparada combinada inactivada contra la infección en conejos del virus de la enfermedad hemorrágica tipo 2 y el Clostridium perfringens tipo A índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Vaccimonitor

versão On-line ISSN 1025-0298

Resumo

REGALADO-FONSECA, Ivis; HERNANDEZ-DE LA ROSA, Lourdes; CASTRO-FIGUEROA, Martha R.  e  ZUMALACARREGUI-DE CARDENAS, Lourdes M.. Processability of nanofilters used in the purification of the recombinant receptor-binding domain protein of severe acute respiratory syndrome type 2 coronavirus. Vaccimonitor [online]. 2024, vol.33  Epub 01-Dez-2024. ISSN 1025-0298.

The active pharmaceutical ingredient and the biological raw material, used for the formulation of the SOBERANA® vaccines, are produced at the Molecular Immunology Center. The antigen of these vaccines is the receptor-binding domain protein of the severe acute respiratory syndrome type 2 coronavirus. The production of this recombinant protein is based on the culture of Chinese hamster ovary cells in stirred tank bioreactors. The technological process on an industrial scale consists of several stages: preparation of culture media and solutions, fermentation, clarification of supernatant and purification. In biotechnological processes derived from cell lines of animal origin, endogenous or adventitious viral contamination is a potential risk. For this reason, a specific step for viral removal by nanofiltration is used in the purification process. The nanofilters used are disposable materials that significantly influence the cost of the process. The processing capacity of the nanofilters in the purification process in question is currently unknown, being the objective of the present investigation with a view to reducing production costs. The processing capacity of the Virosart CPV filters was determined to be 239.74 g/m2 (71.67% saturation) and 1,259 g/m2 (67.82% saturation) for the dimer species and the mixture, respectively. The decrease in the production cost of the nanofiltration stage was determined, representing a 54.85% decrease in the filtration cost for the dimer species and a 25% decrease for the mixture.

Palavras-chave : filters; membrane filtration; nanopores; vaccines.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )